Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 2, 2016, Pages 156-164

  Degasperi, Elisabetta ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DISEASE SURVEILLANCE; HEART DISEASE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORTALITY RATE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; COMPLICATION; GLOBAL HEALTH; INCIDENCE; LIVER TUMOR; PATHOLOGY; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; GLOBAL HEALTH; HUMANS; INCIDENCE; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTORS;

EID: 84995902511     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30018-8     Document Type: Review

References (63)

1. 1 Jemal, A, Bray, F, Center, MM, et al. Global cancer statistics. CA Cancer J Clin 61 (2011), 69–90.
2. 2 El Serag, HB, Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 (2012), 1264–1273.
3. 3 Adams, LA, Lindor, KD, Nonalcoholic fatty liver disease. Ann Epidemiol 17 (2007), 863–869.
4. 4 Younossi, ZM, Koenig, AB, Abdelatif, D, et al. Global epidemiology of non-nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 64 (2016), 73–84.
5. 5 Ng, M, Fleming, T, Robinson, M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
6. 6 Flegal, KM, Carrol, MD, Kit, BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307 (2012), 491–497.
7. 7 Wong, VW, Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 28 (2013), 18–23.
8. 8 Mittal, S, Sada, Y, El-Serag, HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the Veteran Affairs Population. Clin Gastroenterol Hepatol 13 (2015), 594–660.
9. 9 Bruix, J, Sherman, M, Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
10. 10 Wong, RJ, Cheung, R, Ahmed, A, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology 59 (2014), 2188–2195.
11. 11 Younossi, ZM, Otgonsuren, M, Henry, L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
12. 12 Vernon, G, Baranova, A, Younossi, ZM, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
13. 13 Park, JW, Chen, M, Colombo, M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 35 (2015), 2155–2166.
14. 14 Oda, K, Uto, H, Matawari, S, et al. Clinical features of hepatocellular carcinoma associated with non-alcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol 8 (2015), 1–9.
15. 15 Ascha, M, Hanouneh, IA, Lopez, R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with alcoholic steatohepatitis. Hepatology 51 (2010), 1972–1978.
16. 16 Dyson, J, Jacques, B, Chattopadyhay, D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
17. 17 Farrell, GC, Wong, VW, Chitturi, S, NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol 10 (2013), 307–318.
18. 18 Fan, JG, Farrell, GC, Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50 (2009), 204–210.
19. 19 Xu, C, Yu, C, Ma, H, Xu, L, Miao, M, Li, Y, Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 108 (2013), 1299–1304.
20. 20 Arase, Y, Kobayashi, M, Suzuki, F, et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 42 (2012), 264–272.
21. 21 Yatsuji, S, Hashimoto, E, Tobari, M, Taniai, M, Tokushige, K, Shiratori, K, Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 24 (2009), 248–254.
22. 22 Lee, SS, Jeong, SH, Byoun, YS, et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer, 13, 2013, 335.
23. 23 Lee, YC, Cohet, C, Yang, YC, et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 38 (2009), 1497–1511.
24. 24 El-Serag, HB, Tran, T, Everhart, JE, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 (2004), 460–468.
25. 25 Davila, JA, Morgan, RO, Shaib, Y, McGlynn, KA, El-Serag, HB, Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54 (2005), 533–539.
26. 26 Harrison, SA, Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 40 (2006), 68–76.
27. 27 Bosetti, C, Rosato, V, Polesel, J, et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer 64 (2012), 643–651.
28. 28 El-Serag, HB, Hampel, H, Javadi, F, The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4 (2006), 369–380.
29. 29 Larsson, SC, Wolk, A, Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97 (2007), 1005–1008.
30. 30 Nair, S, Mason, A, Eason, J, Loss, G, Perrillo, RP, Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 36 (2002), 150–155.
31. 31 Turati, F, Talamini, R, Pelucchi, C, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 108 (2013), 222–228.
32. 32 Chalasani, N, Younossi, Z, Lavine, J, et al. The diagnosis and management of non-nonalcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2022.
33. 33 Sookoian, S, Castaño, GO, Pirola, CJ, Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut 63 (2014), 530–532.
34. 34 Hashimoto, Y, Hamaguchi, M, Kojima, T, et al. Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J Gastroenterol Hepatol 30 (2015), 546–552.
35. 35 Lau, K, Baumeister, SE, Lieb, W, et al. The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women. Aliment Pharmacol Ther 41 (2015), 467–476.
36. 36 Loomba, R, Yang, HI, Su, J, Brenner, D, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol 177 (2013), 333–342.
37. 37 Salomao, MS, Yu, WM, Brown, RS, et al. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34 (2010), 1630–1636.
38. 38 Salomao, M, Remotti, H, Vaughan, R, et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43 (2012), 737–746.
39. 39 Shibahara, J, Ando, S, Sakamoto, Y, et al. Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 64 (2014), 951–962.
40. 40 Sorrentino, P, D'Angelo, S, Ferbo, U, et al. Liver iron excess in patients with hepatocellular carinoma developed on non-alcoholic steato-hepatitis. J Hepatol 50 (2009), 351–357.
41. 41 Caldwell, SH, Lee, VD, Kleiner, DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol 8 (2009), 346–352.
42. 42 Paradis, V, Zalinski, S, Chelbi, E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49 (2009), 851–859.
43. 43 Omata, M, Lesmana, LA, Tateishi, R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 18 (2010), 439–474.
44. 44 European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
45. 45 Singal, AG, Yopp, AC, Gupta, S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res 5 (2012), 1124–1130.
46. 46 Della Corte, C, Colombo, M, Surveillance for hepatocellular carcinoma. Semin Oncol 39 (2012), 384–398.
47. 47 Musso, G, Gambino, R, Cassader, M, Pagano, G, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
48. 48 Kwok, R, Tse, YK, Wong, GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 39 (2014), 254–269.
49. 49 Roskams, T, Kojiro, M, Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 30 (2010), 17–25.
50. 50 Sangiovanni, A, Manini, MA, Lavarone, M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59 (2010), 638–644.
51. 51 Vilana, R, Forner, A, Bianchi, L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51 (2010), 2020–2029.
52. 52 Iavarone, M, Piscaglia, F, Vavassori, S, et al. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. J Hepatol 58 (2013), 1188–1193.
53. 53 Viganò, L, Conci, C, Cescon, M, et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol 63 (2015), 93–101.
54. 54 Reddy, SK, Steel, JL, Chen, HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 55 (2012), 1809–1819.
55. 55 Piscaglia, F, Svegliati-Baroni, G, Barchetti, A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 63 (2016), 827–838.
56. 56 Kurmann, A, Wanner, B, Martens, F, et al. Hepatic steatosis is associated with surgical-site infection after hepatic and colorectal surgery. Surgery 156 (2014), 109–116.
57. 57 Selzner, M, Clavien, PA, Fatty liver in transplantation and surgery. Semin Liver Dis 21 (2001), 105–113.
58. 58 Wong, R, Aguilar, M, Cheung, R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
59. 59 Torres, DM, Williams, CD, Harrison, SA, Features, diagnosis and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 10 (2012), 837–858.
60. 60 Wen, CP, Lin, J, Yang, CY, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 104 (2012), 1599–1611.
61. 61 Piguet, AC, Saran, U, Simillion, C, et al. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. J Hepatol 62 (2015), 1296–1303.
62. 62 Zhang, ZJ, Zheng, ZJ, Shi, R, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97 (2012), 2347–2353.
63. 63 Singh, S, Singh, PP, Singh, AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144 (2013), 323–332.